Methotrexate use does not increase the prevalence of hepatic steatosis: a real-world retrospective nested case-control study

Choi, Yun‐Jung; Lee, Chang-Hun; Kim, In Hee; Park, Eun Hae; Park, SoJeong; Yoo, Wan‐Hee

doi:10.1007/s10067-020-05456-y

Cited by 10 publications

(7 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, other researchers showed an identical prevalence between MAFLD and NAFLD (31.2 vs. 33.2%) by Lin et al (27), 25.9 vs. 25.7% by Wong et al (28), and 27.4 vs. 27.9% by Huang et al (29). In our cohort, the prevalence of NAFLD was 20.5%, which was consistent with that in the Korean (21.1%) and in the Italian (25.0%) RA population (30,31). To our best knowledge, no studies have investigated the epidemiological data of MAFLD in patients with RA yet.…”

Section: Discussionsupporting

confidence: 90%

Association Between Metabolic Dysfunction-Associated Fatty Liver Disease and Cardiovascular Risk in Patients With Rheumatoid Arthritis: A Cross-Sectional Study of Chinese Cohort

Zou

Gao

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

BackgroundThe nomenclature from non-alcoholic fatty liver disease (NAFLD) to metabolic dysfunction-associated fatty liver disease (MAFLD) is considered to identify more cardiovascular disease (CVD) risks in the general population. Patients with rheumatoid arthritis (RA) carry an excess risk for CVD. However, the prevalence of MAFLD and its relationship with CVD risks in RA have not been reported.MethodsThis cross-sectional study retrospectively analyzed clinical data from a Chinese RA cohort. MAFLD was diagnosed according to the criteria proposed by an international expert panel from 22 countries in 2020. CVD risk in patients with RA was estimated by the Prediction for Atherosclerotic Cardiovascular Disease Risk in China with a 1.5 multiplication factor.ResultsAmong 513 included patients with RA, 78.4% were women and the mean ± SD age was 51.8 ± 12.6 years. The prevalence of MAFLD was 21.4%. There were 10.9% patients with RA concomitated with CVD events and 32.4% with a high-estimated 10-year CVD risk. Besides a higher liver fibrosis score and a higher ratio of advanced fibrosis, RA patients with MAFLD had a higher rate of CVD events (17.3 vs. 9.2%) and a higher proportion of high estimated 10-year CVD risk (55.5 vs. 26.1%) than those without. Multivariate logistic regression analysis showed that MAFLD was associated with an increase in CVD events [adjusted odds ratio (AOR) = 2.190, 95% CI 1.135–4.227] and high estimated 10-year CVD risk (AOR = 2.483, 95% CI 1.412–4.365, all p < 0.05).ConclusionMetabolic dysfunction-associated fatty liver disease was associated with increased CVD risk in patients with RA, which implies the importance of early detection and management of MAFLD in patients with RA.

show abstract

Section: Discussionsupporting

confidence: 90%

Association Between Metabolic Dysfunction-Associated Fatty Liver Disease and Cardiovascular Risk in Patients With Rheumatoid Arthritis: A Cross-Sectional Study of Chinese Cohort

Zou

Gao

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

show abstract

“…[28] and 25.9% vs. 25.7% by Wong et al [29]. In our cohort, the prevalence of NAFLD was 20.5%, which was consistent with that in Korean (21.1%) and in Italian (25.0%) RA population [30,31]. To our best knowledge, no studies have investigated the epidemiological data of MAFLD in RA patients yet.…”

Section: Discussionsupporting

confidence: 91%

Comparison of Metabolic Dysfunction-Associated Fatty Liver Disease with Non-Alcoholic Fatty Liver Disease in Identifying Cardiovascular Risk in Chinese Individuals with Rheumatoid Arthritis

Dai

Zou

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: The nomenclature from non-alcoholic fatty liver disease (NAFLD) to metabolic dysfunction-associated fatty liver disease (MAFLD) is considered to identify more cardiovascular disease (CVD) risk in general population, and patients with rheumatoid arthritis (RA) carry an excess risk for CVD. We aimed to compare MAFLD with NAFLD in identifying CVD risk in RA patients.Methods: Clinical data from a Chinese RA cohort were retrospectively analyzed. Hepatic steatosis was defined by abdominal ultrasound examination. CVD risk in RA patients was estimated by the Prediction for Atherosclerotic Cardiovascular Disease Risk in China.Results: Among 513 included RA patients, 78.4% were female and the mean ± SD age was 51.8 ± 12.6 years. The prevalence of MAFLD and NAFLD was 21.4% and 20.5%, respectively. 10.9% RA patients concomitated with CVD events and 32.4% had a high 10-year CVD risk. Multivariate logistic regression analysis showed that both MAFLD and NAFLD were associated with an increase in CVD events (MAFLD: AOR = 2.303; NAFLD: AOR = 2.478) and high 10-year CVD risk (MAFLD: AOR = 3.184; NAFLD: AOR = 2.870, all p < 0.05). The net reclassification index and integrated discrimination improvement indicated no additional CVD events and high 10-years CVD risk were identified when replacing NAFLD with MAFLD in RA patients. Conclusions: Both MAFLD and NAFLD are associated with an increased CVD risk which implies the importance of early detection and management of MAFLD or NAFLD in RA patients. However, new nomenclature of MAFLD identify no additional CVD risk in RA patients.

show abstract

“…These findings suggest an increased risk of NAFLD in patients with RA. Like the previous reports,20–22 we revealed significantly higher IR (1.66, 95% CI 1.18 to 2.33) of NAFLD in newly diagnosed patients with RA than in the non-RA group in a nationwide cohort study. The KM analysis also revealed a significantly higher cumulative incidence of NAFLD in newly diagnosed RA than in the non-RA group during the first 4 years of follow-up.…”

Section: Discussionsupporting

confidence: 85%

“…However, Wagan et al demonstrated no significant association between treatment with MTX or other csDMARDs and the occurrence of NAFLD in the Pakistani cohort of RA 20. To the best of our knowledge, very few studies have investigated the incidence of NAFLD in a large cohort of patient with RA 20–22…”

Section: Introductionmentioning

confidence: 99%

Increased NAFLD risk in newly diagnosed patients with RA during the first 4 years of follow-up: a nationwide, population-based cohort study

Ho,

Chen,

Chen

et al. 2024

BMJ Open

View full text Add to dashboard Cite

BackgroundAlthough the non-alcoholic fatty liver disease (NAFLD) is prevalent in the general population, NAFLD risk in newly diagnosed rheumatoid arthritis (RA) has rarely been explored. In this population-based cohort, we examined NAFLD risk in patients with RA and identified the potential risk factors.DesignRetrospective study.SettingTaiwan.Participants2281 newly diagnosed patients with RA and selected 91 240 individuals without RA to match with patients with RA (1:40) by age, gender, income status and urbanisation level of the residence.OutcomesIn this retrospective study using the 2000–2018 claim data from two-million representative Taiwanese population, we identified and compared the incidence rates (IRs) of NAFLD and alcoholic fatty liver disease (AFLD) between RA and non-RA groups. Using multivariable regression analyses, we estimated adjusted HR (aHR) of NAFLD development in patients with RA compared with individuals without RA, with 95% CIs.ResultsThe incidences of NALFD and AFLD were not significantly different between individuals with RA and without RA during the 17-year follow-up period. However, patients with RA had significantly increased NAFLD risk during the first 4 years after RA diagnosis, with IR ratio of 1.66 fold (95% CI 1.18 to 2.33, p<0.005), but the risk was reduced after the first 4 years. Multivariable regression analyses revealed that aHR was 2.77-fold greater in patients not receiving disease-modifying anti-rheumatic drugs therapy than in non-RA subjects (p<0.05). Old age, women, low-income status and obesity could significantly predict NAFLD development.ConclusionsWe demonstrated elevated risk of NAFLD in patients with RA during the first 4 years after RA diagnosis, and old age, women, low-income status and obesity were significant predictors of NAFLD.

show abstract

Methotrexate use does not increase the prevalence of hepatic steatosis: a real-world retrospective nested case-control study

Cited by 10 publications

References 31 publications

Association Between Metabolic Dysfunction-Associated Fatty Liver Disease and Cardiovascular Risk in Patients With Rheumatoid Arthritis: A Cross-Sectional Study of Chinese Cohort

Association Between Metabolic Dysfunction-Associated Fatty Liver Disease and Cardiovascular Risk in Patients With Rheumatoid Arthritis: A Cross-Sectional Study of Chinese Cohort

Comparison of Metabolic Dysfunction-Associated Fatty Liver Disease with Non-Alcoholic Fatty Liver Disease in Identifying Cardiovascular Risk in Chinese Individuals with Rheumatoid Arthritis

Increased NAFLD risk in newly diagnosed patients with RA during the first 4 years of follow-up: a nationwide, population-based cohort study

Contact Info

Product

Resources

About